Correction: BrainCool AB (publ) - Year End Report 2023 - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Stockpickerns våta dröm: Fem aktier med ”tiotaggar-potential” / Efter kursraset: Tre färska köpråd för fastighetsbolaget

Pressmeddelande

Correction: BrainCool AB (publ) - Year End Report 2023

MFN Publicerad: 29 Feb 2024 17:45
BrainCool

Correction addresses the number of delivered system for quarter four.

Jon Berg, CEO Comments
“Unfortunately, BrainCool has published an incorrect number of delivered systems in the CEO comments for quarter four. This has no impact on the financial statements.
 
The correct comment should be:
We succeeded in delivering around 25 systems in December and in total 37 systems for quarter four. For the year as whole, we delivered over 70 systems.
 
We are very sorry for the mistake.”

Contact
For more information
Jon Berg - CEO
+46 722 50 91 19
e-mail: [email protected]

About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.

This information is information that BrainCool is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-29 17:45 CET.

Attachments
Year End Report Q4 2023 Correction

Bifogade filer

Year End Report Q4 2023 Correctionhttps://storage.mfn.se/74db2574-c800-4ea1-830e-548b382441a7/year-end-report-q4-2023-correction.pdf

Nyheter om BrainCool

Läses av andra just nu

Om aktien BrainCool

Senaste nytt